EMCDDA (EUDA): The EU's Drug Monitoring Agency and Cannabis

The European Monitoring Centre for Drugs and Drug Addiction — rebranded in 2024 as the European Union Drugs Agency (EUDA) with an expanded mandate — serves as the EU's authoritative source for drug-related data, analysis, and policy guidance. Based in Lisbon, Portugal, the agency collects and analyzes data from all 27 EU member states plus Norway and Turkey through its network of national focal points (the Reitox network). For the cannabis sector, EUDA's work is particularly relevant because cannabis is the most commonly used illicit drug in Europe, and the agency's data and analysis directly influence national and EU-level policy discussions about regulation, public health interventions, and law enforcement approaches. UEDA's cannabis-related work spans prevalence surveys, treatment data analysis, supply market monitoring, legal and policy tracking, and early warning on new developments such as high-potency products and synthetic cannabinoids. The agency publishes the annual European Drug Report, which includes comprehensive cannabis market analysis, as well as specialized publications on cannabis-specific topics. For investors, operators, and policymakers in the European cannabis space, EUDA data represents the most systematic and comparable cross-country information available on cannabis use patterns, policy trends, and market indicators.

EUDA's data collection on cannabis covers five key domains: prevalence and patterns of use, health consequences and treatment demand, drug supply and markets, drug-related law enforcement, and drug policy and legal frameworks. Prevalence data comes from the General Population Survey framework, which standardizes methodologies across member states to enable cross-country comparisons. According to EUDA data, approximately 8% of EU adults (aged 15-64) report past-year cannabis use, with rates significantly higher among young adults (15-34) at approximately 15%. Country-level variation is substantial — past-year use ranges from 2-3% in Eastern European countries to 12-15% in France, the Czech Republic, and the Netherlands. These prevalence figures inform market sizing estimates for both medical and recreational cannabis and provide baseline data for evaluating the public health impacts of regulatory changes.

Treatment data collected through EUDA's Treatment Demand Indicator reveals that cannabis is the most frequently reported primary drug among new clients entering specialized drug treatment across Europe, accounting for approximately 30% of new treatment entries. This data point is frequently cited in policy debates by both proponents and opponents of cannabis reform — opponents argue it demonstrates cannabis-related harm, while proponents note that many cannabis treatment entries are driven by criminal justice referrals rather than voluntary help-seeking, and that treatment outcomes for cannabis use disorder are generally more favorable than for other substances. EUDA also tracks health indicators including emergency department presentations, hospitalizations, and (in limited scope) cannabis-related mortality, providing data that informs both clinical practice guidelines and regulatory impact assessments.

The supply and market monitoring function of EUDA has become increasingly sophisticated, incorporating seizure data, potency tracking, price monitoring, and analysis of new product types entering the European market. EUDA data shows that average THC potency in cannabis resin (hashish) sold in Europe has increased significantly over the past decade, reaching approximately 20-28% THC in some markets, while herbal cannabis potency has stabilized at approximately 10-15% THC. Price data reveals wide variation across Europe, from under 5 euros per gram in Spain and Portugal to over 15 euros per gram in Scandinavian countries. The agency also monitors the emergence of synthetic cannabinoids, high-potency extracts, edibles, and vaporizer products in the European market. For commercial cannabis operators, EUDA market data provides valuable competitive intelligence on pricing, potency preferences, and product format trends across European countries.

EUDA's expanded mandate under the 2024 agency reform (transitioning from EMCDDA to EUDA) gives the agency enhanced capacity for threat assessment, preparedness, and integration of health and security data. The reform was driven in part by the rapidly evolving cannabis policy landscape across Europe and the need for more dynamic monitoring capacity. The agency now has authority to issue alerts about specific drug-related threats, conduct health threat assessments, and provide more proactive policy guidance to member states. For the cannabis sector, this expanded role means EUDA will play an increasingly influential role in shaping the evidence base that informs national regulatory decisions about medical cannabis access, CBD product regulation, and potential recreational legalization. The agency's emphasis on evidence-based policymaking aligns with the interests of the legitimate cannabis industry, which benefits from data-driven regulatory approaches over ideologically motivated policies.